The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $12.22

Today's change-0.01 -0.08%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $12.22

Today's change-0.01 -0.08%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc down slightly

Sarepta Therapeutics Inc closed down just (U.S.)$0.01 Friday to (U.S.)$12.22. Over the last five days, shares have gained 2.86%, but are down 68.33% for the last year to date. Shares have outperformed the S&P 500 by 3.87% during the last year.

Key company metrics

  • Open(U.S.) $12.08
  • Previous close(U.S.) $12.23
  • High(U.S.) $12.28
  • Low(U.S.) $11.68
  • Bid / Ask-- / --
  • YTD % change-68.33%
  • Volume1,335,359
  • Average volume (10-day)1,540,511
  • Average volume (1-month)2,053,766
  • Average volume (3-month)2,077,400
  • 52-week range(U.S.) $11.10 to (U.S.) $41.97
  • Beta1.36
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$4.83
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-739,870.40%

Sarepta Therapeutics Inc has a net profit margin of -739,870.40%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense52426245
Selling / general / administrative15132314
Research & development37293931
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income-52-42-62-45
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-52-42-62-44
Income after tax-52-42-62-44
Income tax, total--------
Net income-52-42-62-44
Total adjustments to net income--------
Net income before extra. items-52-42-62-44
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-52-42-62-44
Inc. avail. to common incl. extra. items-52-42-62-44
Diluted net income-52-42-62-44
Dilution adjustment--------
Diluted weighted average shares42414141
Diluted EPS excluding extraordinary itemsvalue per share-1.25-1.01-1.49-1.07
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.25-1.01-1.49-1.07